Nutanix (NTNX) Received Wells Fargo’s Coverage; MULTICELL TECHS (MCET) SI Increased By 69.11%

November 15, 2017 - By reb123z

MULTICELL TECHS INCORPORATED (OTCMKTS:MCET) had an increase of 69.11% in short interest. MCET’s SI was 41,600 shares in November as released by FINRA. Its up 69.11% from 24,600 shares previously. It closed at $0.0001 lastly. It is down 0.00% since November 15, 2016 and is . It has underperformed by 16.70% the S&P500.

Among 22 analysts covering Nutanix (NTNX), 17 have Buy rating, 0 Sell and 5 Hold. Therefore 77% are positive. Nutanix has $4100 highest and $1900 lowest target. $29.93’s average target is 5.46% above currents $28.38 stock price. Nutanix had 58 analyst reports since September 30, 2016 according to SRatingsIntel. The firm earned “Outperform” rating on Tuesday, October 25 by RBC Capital Markets. The firm has “Hold” rating by Raymond James given on Friday, May 26. The firm earned “Buy” rating on Wednesday, July 19 by RBC Capital Markets. As per Wednesday, June 28, the company rating was maintained by Oppenheimer. The firm has “Buy” rating given on Monday, October 23 by Piper Jaffray. The firm has “Buy” rating given on Monday, June 26 by Credit Suisse. The stock of Nutanix Inc (NASDAQ:NTNX) earned “Buy” rating by Bank of America on Thursday, April 6. On Friday, May 26 the stock rating was maintained by Robert W. Baird with “Buy”. The firm earned “Buy” rating on Friday, May 26 by William Blair. The rating was initiated by FBN Securities with “Sector Perform” on Wednesday, January 11.

Analysts await Nutanix Inc (NASDAQ:NTNX) to report earnings on November, 30 after the close. They expect $-0.56 earnings per share, down 14.29% or $0.07 from last year’s $-0.49 per share. After $-0.58 actual earnings per share reported by Nutanix Inc for the previous quarter, Wall Street now forecasts -3.45% EPS growth.

About 8,279 shares traded. Nutanix Inc (NTNX) has 0.00% since November 15, 2016 and is . It has underperformed by 16.70% the S&P500.

Nutanix, Inc. is a United States-based company, which provides an enterprise cloud platform that converges silos of server, virtualization and storage into an integrated solution. The company has market cap of $4.38 billion. The Company’s enterprise cloud platform connects to public cloud services. It currently has negative earnings. It has activities in the United States; Europe, the Middle East and Africa; Asia-Pacific, and Other Americas.

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $500,090. The Firm and its subsidiaries are developing therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer and interventional cardiology, and peripheral vessel applications. It currently has negative earnings. The Company’s portfolio of lead drug candidates is in various stages of discovery optimization, and preclinical and clinical development, and includes MCT-125, MCT-465, MCT-475 and MCT-485.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.